Evidence derived from mouse models also supports the functional role of p38 MAPK in muscle differentiation (Perdiguero et al., 2007) . In an effort to dissect the role of different p38 MAPK isoforms in myogenesis, Perdiguero et al used p38α, p38 , p38 , and p38δ-deficient mice and analyzed the function of each. p38α rather than p38 and p38 -deficient myoblasts failed to form multinucleated myotubes, whereas p38δ-deficient myoblasts exhibited attenuated differentiation (Perdiguero et al., 2007) . Although a wide body of evidence supports the pro-myogenic role of p38 MAPK, several reports also imply the involvement of p38 MAPK in muscle cell proliferation. The concomitant activation of p38 MAPKα/ and satellite cells imply that p38 MAPK may also be involved in satellite cell activation, since blockade of p38 MAPK by pharmacological inhibitors of p38 MAPK prevents both satellite cell proliferation and differentiation (Jones et al., 2005; Shi et al., 2010) . A recent study using p38 -deficient mice revealed that muscles lacking this isoform of p38 MAPK contain 50% less satellite cells, and these cells exhibit reduced proliferation (Gillespie et al., 2009) implying that this p38 MAPK isoform may also be an important regulator of satellite cell deposition and proliferation.
Although a critical role for ERK1/2 in satellite cell proliferation is established, surprisingly the role of ERK1/2 in myogenesis has not been well defined. Conflicting data from various groups suggest that this pathway may be tailored to respond to distinct cellular and extracellular conditions. Using 10T1/2 fibroblasts, Gredinger el showed that MEK1 and/or Raf1 positively regulates myogenesis by enhancing MyoD transcriptional activity, addition of the MEK inhibitor PD098059 represses MyoD-responsive genes (Gredinger et al., 1998) . PD098059 also partially inhibits the formation of multinucleated myotubes in C2 myoblasts (Gredinger et al., 1998) . In contrast, others have reported a negative effect of ERK1/2 in the regulation of myogenesis (Dorman and Johnson, 1999; Weyman and Wolfman, 1998) . In 23A2 and C2C12 myoblasts, IGF-1 and FGF-2 inhibit myoblast differentiation through ERK1/2 signaling as PD098059 blocked this effect (Kontaridis et al., 2002; Weyman and Wolfman, 1998) . Persistent activation of Raf/MEK/ERK1/2 by overexpression of a constitutively active Raf inhibits the fusion of embryonic chick myoblasts into multinucleated myotubes. This inhibition can be rescued by addition of PD098059 (Dorman and Johnson, 1999 ). Yet there is another layer of regulation of Ras/Raf/ERK1/2 on myogenesis. A novel regulator of the Ras-Raf interaction, named DA-Raf, lacks the Raf kinase domain and interferes with the binding of Ras to other targets. It was found that DAwww.intechopen.com
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Raf serves as a positive regulator of myogenic differentiation (Yokoyama et al., 2007) . A recent study revealed that Grb2-associated binder 1 (Gab1) interacts with the protein tyrosine phosphatase SHP-2 to activate downstream ERK signaling, thereby inhibiting IGF-1-mediated myogenic differentiation (Koyama et al., 2008) . These results are consistent with other data in which conditional deletion of SHP-2 in skeletal muscle impairs skeletal muscle growth (Fornaro et al., 2006) . Taken together, these findings tend to support the notion that ERK1/2 signaling promotes myoblast proliferation and inhibits myogenic differentiation. However, further genetic data using ERK-deficient mice needs to be provided to fully conclude the relevance of ERK1/2 in myoblast proliferation and differentiation.
ERK5 is a novel member of the MAPK family and its physiological function in myogenesis remains to be fully defined. ERK5 is enriched in skeletal muscle, it is activated upon myogenic differentiation, and anti-sense RNA to ERK5 blocks entry into myogenesis (Dinev et al., 2001) . A recent study revealed an essential role of ERK5 in muscle cell fusion through the transcription factors Sp1 and Klf2/4 (Sunadome et al., 2011) . ERK5 has also been shown to be responsible for muscle cell fusion without interference with other differentiation processes (Sunadome et al., 2011) .
Although the JNK pathway has been implicated in myoblast proliferation (Perdiguero et al., 2007) its role in myogenic differentiation remains controversial. JNK has been demonstrated to be either dispensable or negative for myogenesis (Gallo et al., 1999; Khurana and Dey, 2004; Meriane et al., 2002) . It would be extremely informative if myoblasts derived from mice lacking either of the JNK isoforms were analyzed for their effects on cell proliferation and differentiation to resolve these issues.
Duchenne muscular dystrophy
The most common form of muscular dystrophy is Duchenne muscular dystrophy (DMD) which affects up to 1:3,500 males in the United States (Porter, 2000) . The regenerative capacity of skeletal muscle in DMD-stricken patients is impaired due to the loss of dystrophin (Davies and Nowak, 2006) . DMD patients lose muscle strength and mobility and the disease often results in death. There is neither a cure, nor an effective treatment for DMD, or similar skeletal muscle degenerative diseases (Bhatnagar and Kumar, 2010; Tedesco et al., 2010) . DMD is caused by the loss or partial deficiency in the dystrophin protein, which serves as a critical component of the dystrophin glycoprotein complex (DGC) linking the cytoskeleton of the muscle fibers to that of the extracellular matrix. The loss of dystrophin cripples the functionality of the DGC rendering the muscle fiber more susceptible to stress-induced injury. Although the primary defect of DMD is the loss of dystrophin, there are multiple secondary events that contribute to the progression of the disease. These include profound inflammatory responses, extracellular matrix degradation and fibrosis. Strategies therefore that curtail some of these secondary responses have been considered as potential therapeutic avenues to treating the progression of the disease in DMD patients.
Although the DGC and its components such as dystrophin appear to primarily serve structural roles to couple the muscle fiber to the extracellular matrix, there is clearly an important intracellular role played by providing a platform from which signaling pathways are launched. These links to downstream pathways suggest that the DGC engages active signaling in order to regulate muscle fiber function. Hence, DGC dysregulation may lead to alterations in intracellular signaling cascades, which may contribute to the pathogenesis of the muscular dystrophies. In this regard, understanding the signaling pathways such as the MAPKs in skeletal muscle function and muscular dystrophy may provide important insight into new avenues of therapies for these diseases.
MAPKs and Muscular dystrophy
A link between the MAPKs and muscular dystrophy has been indirectly suggested by the fact that the DGC not only functions as a mechanical infrastructure to stabilize skeletal muscle cell membranes, but it also serves as a bridge between stimuli from the extracellular matrix and intracellular signaling through physically interacting with distinct proteins (Rando, 2001) . For example, Grb2, an adapter protein involved in MAPK signal transduction and cytoskeletal organization, interacts with -dystroglycan at the C-terminal proline-rich domains (Yang et al., 1995) . Furthermore, -dystroglycan can physically interact with MAPK kinase 2 (MEK2) and its downstream kinase ERK1/2 in a yeast two-hybrid screen (Spence et al., 2004) . These findings imply that MAPK signaling may play an important role in the mechano-and signal transduction of extracellular stimuli to intracellular biological responses that control muscle fiber viability. However, the reports regarding the activity of the MAPKs in the pathogenesis of muscular dystrophy remain inconclusive and vary in different experimental settings. For example, it has been reported that JNK1 is highly activated in a mouse model of DMD (mdx mouse) and compound intercrosses between an mdx mouse and a MyoD-deficient mouse (mdx/MyoD -/-) contributes to the progressive dystrophinopathy without appreciable changes in either ERK1/2 or p38 MAPK activities (Kolodziejczyk et al., 2001) . In contrast, stable over-expression of the JNK1-specific upstream kinase MKK7 disrupts the formation of myotubes in C2C12 skeletal myoblasts and H9C2 cardiac myoblasts (Kolodziejczyk et al., 2001) . Adenoviral infection of the JNK1 specific inhibitor JIP1 (JNK interacting protein) increased the diameter of myofibers (Kolodziejczyk et al., 2001) , suggesting that the MAPKs can affect the structural integrity of the myofiber. In an attempt to test whether loss of dystrophin causes aberrant mechanotransduction, Kumar et al measured the activity of the MAPKs following stretching of mdx and wild type diaphragm muscles. ERK1/2, but not JNK or p38 MAPKs were significantly activated in the muscles derived from mdx mice (Kumar et al., 2004) . In addition, the downstream effector of ERK1/2, AP-1 was highly up-regulated (Kumar et al., 2004) . In another exercise model, mdx mice were subjected to treadmill exercise, p38 MAPK and ERK1/2, but not JNK1 were highly elevated in mdx cardiac muscles in comparison with wild type muscles (Nakamura et al., 2002) . Elevated p38 MAPK was also observed in utrophin-dystrophin double knock-out cardiac muscles (Nakamura et al., 2001) . Together, these findings suggest that MAPK signaling is likely involved in the pathogenesis of muscular dystrophy, but to what extent and how exactly MAPK contributes at the molecular level to the pathogenesis of DMD remains to be established.
MAPK phosphatases in skeletal muscle function and muscular dystrophy
Equally important as the activation of the MAPKs is their inactivation, which is catalyzed by the MKPs. The MKPs belong to a sub-class of protein tyrosine phosphatases known as the dual-specificity protein phosphatases (DUSP) (Boutros et al., 2008; Soulsby and Bennett, www.intechopen.com Mitogen-Activated Protein Kinases and Mitogen-Activated Protein Kinase Phosphatases in Regenerative Myogenesis and Muscular Dystrophy 163 2009; Tonks, 2006) . The DUSPs are characterized by a consensus signature motif represented by HC(X) 5 R which defines the active site of these enzymes (Soulsby and Bennett, 2009; Tonks, 2006) . MKPs inactivate the MAPKs by directly dephosphorylating the MAPKs on its regulatory threonine and tyrosine residues. The MKPs share largely the same structure comprising of a cdc25 homology domain and a MAPK binding domain in the NH 2 terminus and a COOH-terminus PTP catalytic domain. The NH 2 terminus of the MKPs controls MAPK binding and sub-cellular targeting (Wu et al., 2005) , both of these attributes contribute to MAPK signaling specificity. In this regard, although the MKPs dephosphorylate the MAPKs they do so with varying degrees of potency that depends upon both their MAPK binding affinity and sub-cellular localization. There are 10 catalytically active members in this group and they exhibit distinct sub-cellular localization, responses to extracellular stimuli, tissue distribution and affinity to their substrates (Boutros et al., 2008; Groom et al., 1996; Ishibashi et al., 1994; Misra-Press et al., 1995; Muda et al., 1997; Noguchi et al., 1993; Rohan et al., 1993) .
Binding of MKPs to their MAPK substrates increases phosphatase activity (Camps et al., 1998a; Hutter et al., 2000; Slack et al., 2001) and this is due to stabilization of the active enzyme-substrate complex (Field et al., 2000) . MKP-3 exhibits high fidelity to its substrate ERK1/2 and upon binding its catalytic activity is enhanced (Camps et al., 1998b) . Despite the fact that the MKPs dephosphorylate a common pool of MAPKs these enzymes exhibit remarkably unique physiological effects (Chi et al., 2006; Christie et al., 2005; Wu et al., 2006) . Studies from MKP knock-out mice provide convincing genetic evidence to support the notion that these MKPs function in distinct ways (Nunes-Xavier et al., 2011) . The complexity of the signaling pathways and biological responses that the MKPs are involved with strongly suggest that these enzymes serve as central players in the regulation of the MAPKs. Therefore, the MKPs, which have the capacity to regulate multiple MAPKs simultaneously, represent a critical signaling node of MAPK convergence. Molecules that act as signalling (before nodes) in signal transduction can be defined as those which represent a point of convergence of multiple pathways, and one that is represented by several isoforms that are both positively and negatively involved in divergent signaling. We propose that the MKPs satisfy these criteria and constitute a critical signaling node in the MAPK pathway. Given the established role of the MAPKs in skeletal myogenesis, the actions of the MKPs as critical signaling nodes of the MAPKs is likely to make them important players in this system.
MKPs in skeletal myogenesis and skeletal muscle function.
Studies of the MKPs in myogenesis and skeletal muscle function remain mainly an uncharted area. Much of the work on the MKPs in skeletal muscle function has focused on the role of MKP-1. The first MKP to be implicated in skeletal muscle function was MKP-1 (Bennett and Tonks, 1997) . MKP-1 is a ubiquitously expressed, nuclear localized dual-specificity phosphatase, whose substrates include predominantly p38 MAPK, JNK and to a lesser extent, ERK1/2 (Boutros et al., 2008; Owens and Keyse, 2007) . MKP-1 is an immediate-early gene and is induced by numerous stresses (Owens and Keyse, 2007) . Initial reports demonstrated that MKP-1deficient mice exhibit an unremarkable phenotype, suggesting that the MKPs largely serve redundant physiological roles (Dorfman et al., 1996) . However, we have shown that mice lacking MKP-1 exhibit enhanced ERK1/2, JNK and p38 MAPK activities in skeletal muscle, as well as in other tissues, demonstrating that MKP-1 plays an essential physiological role as a negative regulator of the MAPKs . The earliest suggestion that MKP-1, and hence the MAPKs, participate in myogenic regulation emerged from studies in which conditional overexpression of MKP-1 was shown to stimulate precocious myogenesis in the context of the inhibitory actions of growth factors (Bennett and Tonks, 1997) . MKP-1 expression levels in proliferating myoblasts are initially high, at levels presumably sufficient to allow cell proliferation but not differentiation, and declines upon the onset of myogenesis, suggesting that extinguishing the expression of MKP-1 might be a prerequisite for myogenic entry and/or progression (Bennett and Tonks, 1997; Kondoh et al., 2007; Perdiguero et al., 2007) . Consistent with this, overexpression of MKP-1 when myoblasts have become irrevocably committed to myogenesis inhibits multinucleated myotube formation (Bennett and Tonks, 1997; Kondoh et al., 2007) . Hence, MKP-1 plays both positive and negative roles in myogenesis in a temporal manner by selectively regulating one or more MAPKs (Figure  1) . MKP-1 appears to be directly coupled to the myogenic transcriptional machinery as studies have shown that MKP-1 is a target for upregulation by MyoD (Shi et al., 2010) . Within the proximal promoter of MKP-1 there resides an E-box binding site that serves to mediate MKP-1 activation by MyoD (Shi et al., 2010) . Hence, upon the initiation of myogenesis the activation of MyoD leads to an initial upregulation of MKP-1, which may be required to inactivate ERK1/2 and thus facilitate cell cycle exit in the transition towards myogenic entry. Later on during myogenesis MyoD was shown to uncouple from the MKP-1 promoter and hence downregulate MKP-1 expression (Figure 1) . Downregulation of MKP-1 during the later stages of myogenesis may facilitate the increased p38 MAPK activation, which is important for multinucleated myotube formation. As such, the complexity of the outcome through which MKP-1 integrates multiple MAPK activities cannot be simply inferred by the implied actions of a single MAPK family member. These results using cultured myoblast cell lines are supported by in vivo data where it has been shown that regenerative myogenesis in response to cardiotoxin-induced injury is impaired in MKP-1deficient mice (Shi et al., 2010) . These results support the notion that MKP-1 is an important regulator of myogenesis.
MKP-1 is also implicated in adult skeletal muscle fiber specialization (Shi et al., 2008) . Overexpression of MKP-1 in adult type IIb (glycolytic) myofibers converts these fibers to slower-twitch type IIa or type I (oxidative) fibers, suggesting that MKP-1-mediated dephosphorylation of MAPK signaling is required to maintain the glycolytic fiber phenotype through the repression of slow myofibers (Shi et al., 2008) . Consistent with these data, it has been shown that MKP-1-deficient mice are protected from the loss of oxidative myofibers during high fat diet-induced obesity (Roth et al., 2009 ). Hence, decreased MKP-1 expression results in enhanced MAPK signaling, which protects from the loss of glycolytic myofibers by driving oxidative myofiber conversion. The mechanistic basis for these data is based upon the observation that MKP-1 mediates p38 MAPK phosphorylation of the peroxisome proliferator-activated receptor  co-activator 1 (PGC-1) (Roth et al., 2009) , which is required to promote oxidative myofiber conversion. Collectively, these results suggest that MKP-1 plays an essential role in the maintenance of glycolytic/oxidative myofiber composition. MKP-1 is also suggested to be involved in the maintenance of muscle mass (Shi et al., 2009 ). Overexpression of MKP-1 in slow-twitch soleus muscles and in fasttwitch gastrocnemius muscles reduces muscle fiber size, though this reduction in fiber size may go through distinct molecular mechanisms (Shi et al., 2009 ). Fig. 1 . MAPK/MKP signaling coordinates myogenesis. Following myotrauma the MAPKs become activated to drive cell proliferation. MKP-1 is upregulated by these MAPKs and MyoD. MKP-1 sets the threshold of MAPK activity that permits myoblast proliferation [Proliferation Permissive] but not differentiation. Upon the initiation of differentiation, MyoD uncouples from the MKP-1 promoter causing its expression levels to fall, thereby removing the inhibitory actions of MKP-1 on the MAPKs. This allows for higher levels of MAPK activity to be achieved, in particular p38 MAPK, which promotes differentiation [Differentiation Permissive].
MKP-1 also plays a regulatory role in estrogen-related receptor α (ERRα) and PGC-1α mediated myogenic differentiation. Direct up-regulation of MKP-1 by ERRα and PGC-1α at the early stage of myogenesis inactivate ERK1/2 signaling and facilitate the progression of myogensis as MEK inhibition rescues the myogenic defect in ERR -/-myoblasts (Murray and Huss, 2011) . Recent work from this laboratory suggests that other MKPs, in addition to MKP-1, also contribute to the regulation of skeletal muscle function. Mice lacking MKP-5, which interestingly also dephosphorylates predominately p38 MAPK and JNK, exhibit enhanced skeletal muscle regeneration distinct from that observed with MKP-1-deficient mice (H. S. and A.M.B., unpublished observations) . These results suggest that the MKPs might play distinct roles in not only coordinating myogenic activation and progression but they may do so through specific and non-overlapping mechanisms.
A role for MKP-1 in muscular dystrophy. The generation, maintenance, and repair of adult skeletal muscle is critically dependent upon the activation and self-renewal of satellite cells (Wagers and Conboy, 2005) . In response to skeletal muscle injury, myofiber-released growth factors and cytokines stimulate satellite cell proliferation, migration and differentiation by activating signaling cascades including the MAPK pathway. It is thought that the depletion of satellite cells during the progression of DMD is a major factor that precipitates the ultimate failure of muscle function. Therefore, by modulating satellite cell activation, differentiation and/or self-renewal DMD can theoretically be improved.
Several reports have addressed the role of the MAPKs in mdx mice, however there is no underlying consensus as to whether the MAPKs are definitively involved in the pathogenesis of the dystrophic phenotype. Some reports show upregulation of ERK1/2, JNK2 and p38 MAPK (Nakamura et al., 2005) , whereas others have shown a downregulation of p38 MAPK and an upregulation of ERK1/2 (Lang et al., 2004) , yet others find no consistent differences in p38 MAPK (Nakamura et al., 2001) . To study the pathophysiological role of MKP-1 in Duchenne muscular dystrophy, we inter-crossed MKP-1 knockout mice into the mdx background in order to determine whether loss of MKP-1 ameliorates or exacerbates the dystrophic phenotype. The advantage of generating an MKP-1-deficient animal model is that instead of studying an individual MAPK, we examined the integration of several MAPKs that become hyperactivated due to the lack of MKP-1. We found that mdx/mkp-1 -/-mice have reduced body weight and muscle mass in comparison with mdx/mkp-1 +/+ mice (Shi et al., 2010) . The reduction of body weight may be attributed to the chronic elevated levels of inflammation or it is also likely that this is due to an underlying metabolic defect that we have observed in mice lacking MKP-1 that is related to increased energy expenditure (Roth et al., 2009; Wu et al., 2006) . Histological analysis of muscle sections from mdx/mkp-1 -/-mice revealed that MKP-1 deficiency exacerbates the pathogenesis of muscular dystrophy (Shi et al., 2010) . This exacerbation may be accounted for by a combination of two factors that are cell autonomous and/or directly related to defects in satellite cell function as well as a contribution from a hyperactivated immune response. Satellite cells from MKP-1-deficient muscles exhibit reduced proliferative capacity whereas precocious differentiation was evident even under high serum conditions (Shi et al., 2010) . Additionally, increased levels of macrophage and neutrophil infiltrates into damaged myofibers in mdx/mkp-1 -/-mice compared to MKP-1 wild type mdx mice, this was observed along with serum and skeletal muscle cytokine levels that are significantly increased in mdx/mkp-1 -/-mice (Shi et al., 2010) . Collectively, these findings suggest that MKP-1 is critical for the regulation of muscle regeneration in DMD by modulating both immune responses and satellite cell proliferation and differentiation (Figure 2) . Further studies employing conditional deletion of MKP-1 in the satellite cell and hematopoietic compartments will be required in order to determine the contribution of MKP-1 in these tissues to the overall skeletal muscle regenerative defect.
Therapeutic targeting of MAPK/MKPs in muscular dystrophy
Research on MKP-1 and its involvement in regenerative myogenesis and muscular dystrophy suggests that MKP-1 may play an important role in the progression of muscular dystrophy and possibly other degenerative skeletal muscle diseases. Therefore, targeting the MAPK/MKP signaling pathway in order to ameliorate skeletal muscle disease and specifically, muscular dystrophy, merits further investigation. However, definitive validation that the MAPK/MKP module is a valid therapeutic target for muscular dystrophy is still lacking. There has been some suggestion that interference with the MAPK/MKP signaling module may have therapeutic value. It has been shown that adenoviral delivery of the JNK1 inhibitory protein, JIP1, can attenuate the pathogenesis of dystrophic fibers (Kolodziejczyk et al., 2001) , implying that inhibition of JNK1 may serve as Figure 1 ). Loss of MKP-1 in a mouse model of Duchennes' muscular dystrophy exacerbates the dystrophic phenotype due to enhanced MAPK activity, which inhibits myoblast proliferation, and ectopically enhances differentiation. In conjunction, MKP-1 has a profound effect in macrophages (Mac) and neutrophils (NF), which as a result of enhanced MAPK activity, in the absence of MKP-1 become hyper-responsive leading to increased inflammatory responses. Together, both the increased inflammatory response and dysfunctional myoblast proliferation and differentiation exacerbates the dystrophic phenotype. a potential therapeutic target for the treatment of certain dystrophies. However, given the uncertain role played by JNK in skeletal muscle regeneration this target should be approached cautiously. A recent study shows that treating dystrophic mice with the free radical scavenger -lipoic acid and L-carnitine improved muscular dystrophy with a concomitant repression of ERK1/2, JNK and p38 MAPK activation (Hnia et al., 2007) . This is quite a provocative result since reactive oxygen species have been shown to inhibit the actions of certain protein tyrosine phosphatases through modification of the catalytic cysteine residue (Tonks, 2005) . Therefore, treatment of dystrophic muscle with free radical scavengers would be predicted to ameliorate the loss of PTP activity, including MKP activity, resulting in increased inactivation of MAPKs. However, it is not yet clear whether the improved myopathy is caused by the decreased activation of a particular MAPK and/or a combination thereof. In an Emery-Dreyfuss muscular dystrophy mouse model, which lacks the inner nuclear membrane protein A-type lamins (LMNA), JNK and ERK1/2 are highly activated in heart tissue and cardiomycytes (Muchir et al., 2007) . Inhibition of the ERK1/2 upstream kinase MEK by PD098059 improves cardiomyopathy in Lmna mutant knock-in mice (Muchir et al., 2009) , implying that molecules in the ERK1/2 pathway have therapeutic potential for the treatment of human Emery-Dreyfuss muscular dystrophy and potentially related disorders.
Although the MAPK/MKP pathway represents a potentially attractive therapeutic target to treat muscular dystrophy, it is a challenging one given the fact that the MAPK/MKP module is a universal pathway serving a number of common control points in the regulation of cell proliferation, differentiation, migration, and survival. The challenge will be to identify MAPK/MKP family members that exhibit signaling preferences to skeletal muscle with those functions further selectively controlling the appropriate physiological response in dystrophic skeletal muscle tissue. Given the importance of p38 MAPK in promoting regenerative myogenesis an attractive strategy could involve enhancing p38 MAPK activity so as to promote either satellite cell activation, proliferation and/or differentiation in dystrophic tissue. This could conceivably be achieved either through activation of p38 MAPK itself or through inhibition of the MKP that opposes the physiologically relevant pool of p38 MAPK in these cells. Clearly, significant gaps in our knowledge need to be filled in this area, nevertheless it is an important goal given the devastating nature of these skeletal muscle diseases that still lack a successful treatment.
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